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Background/Purpose: The purpose of this study is to share experiences diagnosing and treating choroidal
neovascularization (CNV) in young patients (age  50 years) at our hospital.
Methods: The study reviewed retrospective data of patients ( 50 years old) with CNV who received
antivascular endothelial growth factor treatment (anti-VEGF) between January 2007 and August 2012 at
Shin Kong Wu Ho-Su Memorial Hospital. We recorded the total number of injections, types of drugs,
preoperative and ﬁnal best-corrected visual acuity (BCVA), central retinal thickness (CRT) in optical
coherence tomography (OCT), and total follow-up times, and then used two-tailed paired t tests to
compare mean changes in BCVA and CRT on OCT.
Results: The study enrolled 59 patients  50 years of age with CNV diagnosed in 67 eyes. The mean age
was 36.9 ± 10.0 years (range, 8e50 years). Twenty-one patients were male and 38 patients were female.
Forty-two CNV lesions were subfoveal, 19 were juxtafoveal, and ﬁve were extrafoveal. The mean total
follow-up time was 18.5 ± 19.9 months (range, 0.5e71 months). Pathologic myopia was the most
common cause of CNV in this study (47.8%), followed by punctate inner choroidopathy (17.9%), idiopathic
CNV (16.4%), polypoidal choroidal vasculopathy (13.4%), angioid streaks (3.0%), and choroidal rupture
(1.5%). After anti-VEGF treatment, the mean BCVA improved from 0.69 ± 0.61 to 0.42 ± 0.59 (p < 0.05).
CRT decreased from 257.5 ± 48.2 to 210.3 ± 35.7 (p < 0.05). The mean number of injections was 1.9 ± 1.6
(range, 1e9).
Conclusion: In this study we found that pathologic myopia, punctate inner choroidopathy, and idiopathic
and polypoidal choroidal vasculopathy comprised the four most common causes of CNV in patients  50
years of age in Taiwan. We also revealed that anti-VEGF treatment is highly effective in the treatment of
CNV in this age group.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Choroidal neovascularization (CNV) is a common cause of visual
impairment in older adults in developed countries.1e3 CNV is
characterized by new, abnormal blood vessels growing from the
choroid via breakage in Bruch's membrane or the basement
membrane of the retinal pigment epithelium (RPE). These vessels
can leak blood and ﬂuid, and are accompanied by ﬁbrous tissue,e no conﬂicts of interest.
morial Hospital, Number 95,
an.
.-K. Cheng).
ciety of Taiwan. Published by Elsewhich often leads to damage of the retinal tissues and vision
loss.4e6 CNV develops as a consequence of processes related to
wound healing and tissue repair.4 CNV may cause vision loss from
the exudation of intraretinal or subretinal ﬂuid, hemorrhage, or
ﬁbrosis.5 CNV is most commonly seen in patients with exudative
age-related macular degeneration (AMD), which occurs at ages >
50 years.2,7
CNV can also occur in younger patients ( 50 years), who usu-
ally do not have conspicuous drusen or pigmentary abnormalities.
The biomicroscopic ﬁndings of CNV in younger patients are
generally better deﬁned when compared with CNV in older pa-
tients with AMD. The CNV is usually visible as a grayish green
subretinal membrane, surrounded by a halo of pigmentation,
sometimes with clearly visible subretinal blood, ﬂuid, or lipids.5 Invier Taiwan LLC. All rights reserved.
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myopia (PM), angioid streaks, inﬂammatory or infectious condi-
tions [histoplasmosis, sarcoidosis, multifocal choroiditis, punctate
inner choroidopathy (PIC)], choroidal tumors (nevi, melanoma,
hemangioma, osteoma), trauma (choroidal rupture, laser photo-
coagulation), or idiopathic cause.5,6,8 Regardless of the cause, the
vision loss as a result of untreated CNVmay have a major impact on
the daily lives of patients, especially if both eyes are affected. The
initial stimulus that activates the processes leading to the devel-
opment of CNV can arise from several sources, such as lacquer
cracks in pathologic myopia, disruption of the elastic layer of
Bruch's membrane in angioid streaks, or inﬂammatory conditions
in PIC or multifocal choroiditis.4e6
In the past decade, studies have found that antivascular endo-
thelial growth factor (anti-VEGF), such as bevacizumab, ranibizu-
mab, and aﬂibercept, is highly effective in treating CNV in AMD.9e14
However, there are not as many studies of anti-VEGF treatment of
CNV in younger patients compared with patients > 50 years of age.
The purpose of this study is to reveal the clinical characteristics and
the result of anti-VEGF treatment of CNV in young patients (age 
50 years) at our hospital.
2. Materials and methods
This study reviewed a retrospective chart of CNV patients from
January 2007 to August 2012 at Shin Kong Wu Ho-Su Memorial
Hospital, Taipei, Taiwan. The study was approved by the institute
review board of Shin Kong Wu Ho-Su Memorial Hospital and
conformed to the tenet of the Declaration of Helsinki. The study
included patients who were  50 years of age and who were
diagnosed with CNV. All patients had evidence of dye leakage that
represented occult or classic CNV over subfoveal or juxtafoveal
areas in ﬂuorescein angiography (FA) and/or indocyanine angiog-
raphy at baseline. Optical coherence tomography (OCT; Stratus III;
Carl Zeiss, Dublin, CA, USA) also revealed evidence of CNV such as
subretinal ﬂuid, macular edema, RPE detachment (RPED), sub-
retinal or sub-RPE hyperreﬂectivity lesion, derangement of retina-
RPE tissue density, or various combinations of the above ﬁnd-
ings.15 Exclusion criteria were as follows: (1) patients with any
retinal vasculopathies (including diabetic retinopathy, retinal vein
occlusions, retinal vasculitis, etc.); (2) patients with previous sub-
foveal or juxtafoveal laser treatment; (3) patients with advanced
glaucoma or intraocular pressure in the study eye > 22 mmHg in
spite of adequate treatment; and (4) patients with acute ocular or
periocular infection. We recorded the patients' sex, age, lesion side
(subfoveal, juxtafoveal, or extrafoveal), total follow-up time, and
initial best-corrected visual acuity (BCVA) using Snellen charts in
logMAR and Early Treatment Diabetic Retinopathy Study (ETDRS)
charts. Funduscopic examination, OCT, FA, and, if needed, indoc-
yanine angiography were performed on the initial visit for every
patient. In the follow-up period, funduscopic examination and OCT
were performed on every visit, whereas FA and/or indocyanineTable 1
Deﬁnition of CNV types in young patients.
Type of CNV Deﬁnition
PM Myopia > 6 diopter and with characteristic fund
posterior staphyloma
PIC Characteristic fundus features of PIC such as mu
PCV Typical ﬁnding of polypoidal lesion in ICG
Angioid streaks Characteristic feature of irregular narrow streak
Traumatic choroidal rupture Trauma history and linear tear in choroid, Bruch
Idiopathic Absence of any other ophthalmic abnormality
CNV ¼ choroidal neovascularization; ICG ¼ indocyanine angiography; PCV ¼ polypoida
myopia; RPE ¼ retinal pigment epithelium.green angiography were performed at the discretion of attending
physician.
The study employed intravitreal anti-VEGF injection including
bevacizumab and ranibizumab for most patients, except for some
patients with extrafoveal CNV. For those patients who received
anti-VEGF treatment, the following data were recorded: total
number of injections, types of drugs (bevacizumab or ranibizumab)
used, preoperative and ﬁnal BCVA, EDTRS, and central retinal
thickness (CRT). The study also documented other treatment such
as pars plana vitrectomy, photodynamic therapy (PDT), and
photocoagulation therapy.
The study performed statistical analysis using SPSS version 17.0
(SPSS, Chicago, IL, USA). We used two-tailed paired t tests to
compare mean changes in BCVA and CRTon OCT. A value of p < 0.05
was considered statistically signiﬁcant. Values in the text are rep-
resented by mean ± standard deviation.
3. Results
The study enrolled 59 patients (67 eyes)  50 years of age
diagnosed with CNV. We identiﬁed six types of CNV in young pa-
tients, the deﬁnition of which is depicted in Table 1 and includes
CNV associated with PM, PIC, idiopathic cause, polypoidal choroidal
vasculopathy (PCV), angioid streak, and traumatic choroidal
rupture.
Table 2 summarizes all demographic data including mean age,
sex, cause of CNV, lesion site, and follow-up time. Themean agewas
36.9 ± 10.0 years (range, 8e50). Twenty-one patients were male
(35.6%) and 38 patients were female (64.4%). The diagnoses of 32
eyes (47.8%) exhibited PM, 12 eyes (17.9%) exhibited PIC, 11 eyes
(16.4%) exhibited idiopathic CNV (ICNV), nine eyes (13.4%) exhibi-
ted PCV, two eyes (3.0%) exhibited angioid streaks, and one eye
(1.5%) exhibited choroidal rupture. The CNV lesions were subfoveal
in 42 (63.6%) eyes, juxtafoveal in 19 (28.8%) eyes, and extrafoveal in
ﬁve (7.6%) eyes. In one case of PCV, the lesions were ruptured with
vitreous hemorrhage, and therefore the lesion site could not be
classiﬁed.
We administered anti-VEGF drugs, including bevacizumab and
ranibizumab, to treat 63 eyes (32 PM, 9 PIC, 11 idiopathic CNV, 8
PCV, 2 angioid streaks, and 1 choroidal rupture). All lesion eyes in
the category of PM, idiopathic CNV, angioid streaks, and choroidal
rupture received anti-VEGF injection; one eye in PCV received vit-
rectomy without anti-VEGF owing to vitreous hemorrhage; one eye
of PIC was lost in follow up before receiving treatment, and two
eyes in PIC received oral steroid therapy instead of anti-VEGF. The
mean total follow-up time was 18.5 ± 19.9 months (range, 0.5e71).
The mean number of intravitreal injections was 1.9 ± 1.6 (range,
1e9) with 1.7 ± 1.3 in PM, 2.7 ± 2.5 in PIC, 1.6 ± 1.2 in idiopathic
CNV, 2.2 ± 1.1 in PCV, 1.0 ± 0.0 in angioid streaks, and 1.0 in
choroidal rupture (Table 3). We administered two injections of
ranibizumab in PIC and idiopathic CNV, respectively, and others
were given bevacizumab injections. In addition to anti-VEGFus features of PM such as lacquer cracks, patch atrophy, peripapillary atrophy or
ltiple small yellow-white nodular lesions or atrophic scars
s radiated from optic nerve head
membrane, and RPE layer
l choroidal vasculopathy; PIC ¼ punctate inner choroidopathy; PM ¼ pathological
Table 2
Demographic data of patients.
All PM PIC ICNV PCV Angioid streaks Choroidal rupture
No. of patients (%) 59 30 (50.8%) 9 (15.3%) 11 (18.6%) 7 (11.9%) 1 (1.7%) 1 (1.7%)
Sex:
Male 21 (35.6%) 9 (30%) 2 (22.2%) 3 (27.3%) 6 (85.7%) 0 1 (100%)
Female 38 (64.4%) 21 (70%) 7 (77.8%) 8 (72.7%) 1 (14.3%) 1 (100%) 0
Mean age (y) 36.9 ± 10.0 36.2 ± 7.2 25.1 ± 10.6 35.5 ± 8.0 48.0 ± 1.3 50.0 ± 0.0 28.0
No. of eyes (%) 67 32 (47.8%) 12 (17.9%) 11 (16.4%) 9 (13.4%) 2 (3.0%) 1 (1.5%)
Lesion site:a
Subfoveal 42 (63.6%) 20 (62.5%) 6 (50.0%) 10 (90.9%) 3 (37.5%) 2 (100%) 1 (100%)
Juxtafoveal 19 (28.8%) 9 (28.1%) 5 (41.7%) 1 (9.1%) 4 (50.0%) 0 0
Extrafoveal 5 (7.6%) 3 (9.4%) 1 (8.3%) 0 1 (12.5%) 0 0
Follow up time (mo) 18.5 ± 19.9 18.8 ± 20.1 22.8 ± 19.9 23.3 ± 20.9 9.9 ± 20.8 4.0 ± 0.0 4.5
ICNV ¼ idiopathic choroidal neovascularization; PCV ¼ polypoidal choroidal vasculopathy; PIC ¼ punctate inner choroidopathy; PM ¼ pathological myopia.
a One eye was diagnosed as ruptured choroidal neovascularization (CNV) in PCV and therefore was not classiﬁed as a subfoveal or juxtafoveal lesion.
Table 3
Number of intravitreal injections.
All PM PIC ICNV PCV Angioid streaks Choroidal rupture
Number of eye injected 63 32 9 11 8 2 1
Total number of injections 117 55a 24b 18b 17c 2 1
Mean number of injections 1.9 ± 1.6 1.7 ± 1.3 2.7 ± 2.5 1.6 ± 1.2 2.2 ± 1.1 1.0 ± 0.0 1.0
Duration between injections 11.3 ± 1.2 10.9 ± 2.1 10.9 ± 1.3 13.4 ± 1.5 12.1 ± 2.2 1.0 ± 0.0 4.5
Follow-up time (mo) 18.5 ± 19.9 18.8 ± 20.1 22.8 ± 19.9 23.3 ± 20.9 22.9 ± 20.8 1.0 ± 0.0 4.5
ICNV ¼ idiopathic choroidal neovascularization; PCV ¼ polypoidal choroidal vasculopathy; PDT ¼ photodynamic therapy; PIC ¼ punctate inner choroidopathy;
PM ¼ pathological myopia.
a One patient of PM received PDT.
b One injection of ranibizumab in PIC and idiopathic CNV, others were bevacizumab.
c One patient of PCV received focal laser treatment, and 2 received vitrectomy for vitreous hemorrhage; one patient of PM received PDT.
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vitreous hemorrhage, one PCV eye received laser photocoagulation
for juxtafoveal polyp, and one PM eye received PDT. Figs. 1e6 show
the baseline and post-treatment FA and OCT of the cases in each
group.
Tables 4 and 5 summarize the initial and ﬁnal mean BCVA in
logMAR and CRT, and compare the differences using paired t test.
The mean BCVA improved from 0.69 ± 0.61 to 0.42 ± 0.59 after
intravitreal anti-VEGF treatment (p < 0.05) (PM: 0.57 ± 0.46 toFig. 1. A 44-year-old female with pathological myopia (PM) in her right eye. Color fundus
ography (FA) showed obvious dye leakage, and there was (C) a hyperreﬂective lesion w
vascularization was noted then on (E) FA without dye leakage and (F) OCT after intravitrea0.36 ± 0.53, p < 0.05; ICNV: 0.69 ± 0.71 to 0.33 ± 0.57, p < 0.05;
PCV: 1.25 ± 0.84 to 0.81 ± 0.69, p < 0.05; Table 4). Our study also
found improvement trends for BCVA in PIC (0.43 ± 0.51 to
0.27 ± 0.39, p ¼ 0.12). The overall mean CRT showed a parallel
ﬁnding, which decreased from 257.5 ± 48.2 mm to 210.3 ± 35.7 mm
(p < 0.05) (PM: 253.6 ± 40.8 to 207.2 ± 31.2, p < 0.05; ICNV:
272.2 ± 33.9 to 208.2 ± 43.5, p < 0.05; PCV: 286.3 ± 67.7 to
220.9 ± 62.7, p ¼ 0.05; Table 5). We also discovered trends for
decreased CRT in PIC (229.4 ± 38.0 to 202.9 ± 17.1, p ¼ 0.12),(A) before treatment and (D) post-treatment. Before treatment, (B) ﬂuorescein angi-
ith elevation on optical coherence tomography (OCT). Regression of choroidal neo-
l injection of bevacizumab.
Fig. 2. A 29-year-old female with idiopathic choroidal neovascularization (CNV) in the left eye. Fluorescein angiography (FA) revealed (A) obvious dye leakage and (B) hyper-
reﬂective lesion with thickening of retinal pigment epithelium (RPE) and Bruch's membrane. After one injection of bevacizumab, (C) no dye leakage occurred, but staining occurred
on FA and (D) regression of CNV lesion on optical coherence tomography.
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choroidal rupture (216 to 203; 1 eye only). Currently, the study has
registered no serious adverse effects, such as endophthalmitis,
uveitis, retinal detachment, vitreous hemorrhage, lens damage,
stroke, myocardial infarction, exacerbated hypertension, or
gastrointestinal upset.Fig. 3. A 45-year-old manwith polypoidal choroidal vasculopathy (PCV) of the right eye. The
after intravitreal injection of bevacizumab. The initial presentation was ruptured PCV with
leakage, and (C) indocyanine angiography (ICGA) demonstrated the hot spot. (D) Optical c
Subretinal hemorrhage was absorbed and retinal pigment epithelium (RPE) change was le
disappeared in ICGA. (H) OCT revealed absorption of subretinal ﬂuid.4. Discussion
Our study revealed that PM (47.8%) is the most common cause of
CNV in our cohort of 67 eyes of 59 young patients in Taiwan. PM
was followed by PIC (17.9%), ICNV (16.4%), PCV (13.4%), angioid
streaks (3%), and choroidal rupture (1.5%). Cohen et al8 in 1996ﬁrst row shows the picture before treatment and the second row represents the images
(A) subretinal hemorrhage, (B) ﬂuorescein angiography (FA) disclosed a point of dye
oherence tomography (OCT) showed subretinal hemorrhage and subretinal ﬂuid. (E)
ft over. (F) Only a window defect was found in FA and (G) the previous hot spot also
Fig. 4. A 22-year-old women was diagnosed as having punctate inner choroidopathy (PIC) in her left eye. (A) Multiple hyperﬂuorescence lesions were noted on ﬂuorescein
angiography (FA) with one obvious leaking point. (B) The corresponding lesion of choroidal neovascularization (CNV) on optical coherence tomography (OCT). Shrinkage of the CNV
was documented from (C) FA and (D) OCT following antivascular endothelial growth factor (anti-VEGF) injection.
Y.-H. Li et al. / Taiwan Journal of Ophthalmology 5 (2015) 76e8480reported that the etiologies of CNV in 363 young patients in
Western Europe were PM in 62% of the cases, ICNV in 17%, PIC in
12%, angioid streaks in 5%, and miscellaneous hereditary or trau-
matic or inﬂammatory disorders in 4%. Compared with the study of
Cohen et al,8 similar components of the common etiologies were
found in our study aside from PCV, which accounted for the fourth
common etiology in our study. This difference is not surprising,
because the incidence of PCV is higher in Asian populations
compared with Caucasian populations, and the onset age of PCV in
Asian populations is known to be generally younger than typical
AMD.16e20 By contrast, pathologic myopia is the major cause of CNV
in young patients in both Taiwan (47.3%) andWestern Europe (62%).
This common result is interesting because the prevalence of high
myopia (< 6 diopters) is very different between these two areas.
High myopia is much more common in Taiwanese (21%)21 and
Asian populations (6.8e21.6%)22e26 than in European and Cauca-
sian populations (1.4e2.5%).27e29 The predominant prevalence of
high myopia as a risk factor for the development of CNV in young
patients in such different ethnic groups highlights the rarity of
other factors as the cause of development of CNV in patients  50
years of age.
In addition, our study revealed that anti-VEGF is highly effective
in treating CNV with various causes in young patients ( 50 years
old). The effects of anti-VEGF are signiﬁcant not only in overall
BCVA improvement (from logMAR 0.69 ± 0.61 to 0.42 ± 0.59,
p < 0.05), but also in three major categories of etiologies (PM:
0.57 ± 0.46 to 0.36 ± 0.53, p < 0.05; ICNV: 0.69 ± 0.71 to 0.33 ± 0.57,
p < 0.05; and PCV: 1.25 ± 0.84 to 0.81 ± 0.69, p < 0.05; Table 4). Our
study also found trends for improvement in PIC (0.43 ± 0.51 to
0.27 ± 0.39, p ¼ 0.12), angioid streaks (1.35 ± 0.25 to 1.24 ± 0.54; 2
eyes only), and choroidal rupture (0.52 to 0.0; 1 eye only) (Table 4).
We also found parallel improvement of macular edema in each
category and in the overall results (Table 5). For CNV associated
with AMD, frequent injection of anti-VEGF is necessary for main-
taining the initial gain in the improvement of vision9,11; whereas inour study for younger patients with CNV, lower injection rates of a
mean injection of 1.9 ± 1.6 shots of anti-VEGF in a mean follow-up
time of 18.5 ± 19.9 months (mean interval between two injections
is 11.3 ± 1.2 months) could be effective in achieving the beneﬁcial
goal. Chang et al30 also reported the results of intravitreal injection
of bevacizumab for subfoveal CNV in non-AMD patients, with 3.4
mean injections/eye during a mean follow-up time of 58.8 weeks to
achieve a median visual acuity of 20/40 (logMAR, 0.30). The mean
number of injections and the mean duration between two in-
jections had no signiﬁcant difference among PM, idiopathic CNV,
PIC, and PCV in our study (p ¼ 0.21), which implies that the fre-
quency of anti-VEGF injection is similar among younger CNV pa-
tients regardless of the etiology.
Other treatment modalities have been proposed for CNV treat-
ment. For example, thermal laser photocoagulation is very effective
in ablating the CNV lesions. However, laser photocoagulation can
only be applied to extrafoveal or juxtafoveal lesions in order not to
damage the retinal fovea tissue. Even in juxtafoveal lesions, the
long-term results on visual acuity maintenance are limited, due to
the late extension of photocoagulation scars.31e33 In our series, the
majority of lesions in most categories (except PCV) were subfoveal
(Table 2), in which laser photocoagulation might not be suitable for
treatment.
For subfoveal and juxtafoveal CNV, excluding AMD, verteporﬁn
PDT has been shown to be effective in stabilizing vision in many
types of CNV listed in our study, including PM,34,35 PIC,36,37 idio-
pathic CNV,38 and PCV.39,40 However, subsequent studies have
documented limited long-term visual outcome.41e44 Furthermore,
recent studies have shown that anti-VEGF treatment seems to be
more effective than PDT in improving vision in these catego-
ries.45e49 In a prospective, multicenter study comparing the effec-
tiveness of ranibizumab monotherapy with verteporﬁn PDT (the
RADIANCE study) in subfoveal CNV in PM patients, Wolf et al45
revealed that ranibizumab was signiﬁcantly superior to PDT in
improving the visual outcome (10.5e10.6 ETDRS letters in
Fig. 5. A 50-year-old women with angioid streaks in both eyes. For the right eye, (A) color fundus shows the linear radial streaks over the peripapillary area, (B) and (C) show the
pseudoxanthoma elasticum of her lateral and anterior neck, (D) a patch of macular retinal pigment epithelium (RPE) change, (E) dye leakage from subfoveal lesion in ﬂuorescein
angiography (FA), and (F) cystoid macular edema with elevated lesion from RPE. After one injection of bevacizumab, (G) previous RPE change turned out to be a macular scar with
(H) FA staining and total regression of macular edema on optical coherence tomography (OCT) (I).
Fig. 6. A 28-year-old man with choroidal rupture in the left eye. (A) A linear lesion of retinal pigment epithelium (RPE) change on the fundus. (B) Fluorescein angiography (FA)
revealed dye leakage from choroidal neovascularization (CNV) and (C) optical coherence tomography (OCT) revealed the presence of the break in the RPE and Bruch's membrane
with choroidal neovascular membrane. After one intravitreal injection of bevacizumab, (D) a patch lesion of RPE changed. (E) Dye staining along the site of choroidal rupture
occurred and (F) the choroidal neovascular membrane on OCT exhibited shrinkage.
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Table 4
Initial and ﬁnal mean best-corrected visual acuity (BCVA) in logMAR of young choroidal neovascularization (CNV) patients after antivascular endothelial growth factor (anti-
VEGF) treatment.
All PM PIC ICNV PCV Angioid streaks Choroidal rupture
Number of eye injections 63 32 9 11 8 2 1
Initial 0.69 ± 0.61 0.57 ± 0.46 0.43 ± 0.51 0.69 ± 0.71 1.25 ± 0.84 1.35 ± 0.25 0.52
Final 0.42 ± 0.59 0.36 ± 0.53 0.27 ± 0.39 0.33 ± 0.57 0.81 ± 0.69 1.24 ± 0.54 0.0
p < 0.05 < 0.05 0.12 < 0.05 < 0.05
ICNV ¼ idiopathic choroidal neovascularization; PCV ¼ polypoidal choroidal vasculopathy; PIC ¼ punctate inner choroidopathy; PM ¼ pathological myopia.
Y.-H. Li et al. / Taiwan Journal of Ophthalmology 5 (2015) 76e8482ranibizumab group vs. 2.2 letters in PDT alone group, p < 0.00001).
In another study comparing the visual outcomes after anti-VEGF
injection or PDT for ICNV, Kang and Koh47 found that the anti-
VEGF group showed signiﬁcantly better mean BCVA than the PDT
group at each follow-up visit for up to 24 months.
PIC comprised the second category in our series. It is a relatively
uncommon inﬂammatory multifocal chorioretinopathy with a
higher prevalence in young women according to our results
(Table 2). PIC may be regarded as a subtype of multifocal choroiditis
with little or no vitreous inﬂammation.50,51 Although most cases of
PIC had a self-limited disease course, severe visual loss could
develop as a result of CNV formation. Macular CNV was a well
known complication of PIC. In a recent report of complications of 31
eyes with PIC, 64.5% of the investigated eyes were found to have
either past history or active presentation of macular CNV.52 In
another recent report of 112 eyes with PIC in Chinese patients,
Zhang et al53 also found that 64% of investigated eyes had macular
CNV. VEGF was found to be associated with CNV secondary to PIC.
Using immunohistochemical stain, Shimada et al54 found that VEGF
was expressed in all samples of surgically excised CNV in 14 pa-
tients with PIC or multifocal choroiditis. Recently, anti-VEGF has
been found to be very effective in the treatment of CNV associated
PIC. In a prospective study following 12 eyes for 12 months, Zhang
et al46 found that a mean of only 1.9 (1e4) injections were neces-
sary to improve ormaintain vision. In another study following eight
eyes for 24 months, Arevalo et al55 revealed that a mean of only 1.5
(1e3) injections were necessary for the as-needed treatment of
CNV in PIC. These results are very similar to ours, in which a mean
of only 2.7 injections were necessary to maintain the BCVA in PIC
associated CNV in a mean follow-up period of 22.8 months.
Idiopathic CNV comprised the third category in young CNV pa-
tients in our series. Although the deﬁnition of ICNV is usually by
exclusion of other types of CNV, ICNV still has several unique
ﬁndings. For example, the morphology of ICNV is usually of classic
type CNV, and the occurrence of CNV is usually solitary and uni-
lateral.56 According to Ho et al,56 the natural history of ICNV is
usually self-limited. However, severe visual loss might develop in
some patients without treatment, particularly in those with lesions
no smaller than one disc area.56 As with other types of CNV, anti-
VEGF was also found to be very effective in treating ICNV.57,58 In
a prospective study of 40 eyes of ICNV in Chinese patients for 12
months, Zhang et al58 was able to achieve a mean improvement of
2.4 lines with amean of only two injections of bevacizumab. SimilarTable 5
Initial and ﬁnal mean central retinal thickness [CRT (mm)] of young choroidal neovascu
treatment.
All PM PIC I
Number of eyes 63 32 9 1
Initial 257.5 ± 48.2 253.6 ± 40.8 229.4 ± 38.0 2
Final 210.3 ± 35.7 207.2 ± 31.2 202.9 ± 17.1 2
p < 0.05 < 0.05 0.12 <
ICNV ¼ idiopathic choroidal neovascularization; PCV ¼ polypoidal choroidal vasculopathresults were also noted in our series that, with a mean of 1.6 in-
jections of anti-VEGF, signiﬁcant improvement of BCVA (approxi-
mately 3 lines, from 20/81 to 20/40, p < 0.05) was achieved after a
mean follow-up time of 23.3 months.
In the current study, CNV in young patients was more common
in women (64.4%) than in men. This is also noted in Cohen et al's8
report of Western European patients (female 58%). The tendency of
female predominancewas detected in different etiologies including
PM, ICNV, and PIC or inﬂammatory causes. This may suggest the
role of estrogen in the development of CNV in younger patients.59
By contrast, PCV has a predominant male prevalence in our cur-
rent series (men: 75%), which is similar to the PCV in patients > 50
years of age; most studies reported a male predominance.16e18 In
our series, although PCV comprises the fourth prevalent cause of
CNV in patients  50 years old, the mean age of PCV (48.0 ± 1.3
years) is signiﬁcantly older than other major causes (PM 36.2 ± 7.2
years, PIC 25.1 ± 10.6 years, ICNV 35.5 ± 8.0 years, p < 0.05). This
suggests that PCV is probably more like a degenerative disease
similar to AMD, except that the onset age is relatively younger than
the criteria for the deﬁnition of AMD (> 50 years old).
Anti-VEGF has also been found to be effective for the treatment
of PCV in terms of both visual improvement and ﬂuid absorption. In
a long term study (mean follow-up time 42.58 months) for the
treatment of 36 PCV patients, Kang and Koh60 achieved a signiﬁcant
improvement in both BCVA and OCT with a mean of 11.45 ranibi-
zumab injections, which corresponded to a mean interval of 3.72
months between two injections. Our previous study of the annual
result of bevacizumab for treatment of PCV in an older cohort (> 50
years) had a similar frequency of 3.3 injections in 12months follow-
up (mean interval of 3.63 months between two injections).61 By
contrast, the current study revealed that younger patients with PCV
have much less frequency of injections or a much longer interval
between two injections in the PCV group (12.1 ± 2.2 months). This
ﬁnding implies a more sustained effect of anti-VEGF injection in
younger PCV patients.
Our series only included sporadic cases of CNV associated with
angioid streaks and traumatic choroidal rupture, and thus, our
study could not characteristically describe CNV of these two groups.
Anti-VEGF treatment successfully reduced the activity of CNV in
both patients and maintained or improved the visual outcome in
these two patients. Recently, anti-VEGF has also been advocated as
an effective treatment modality for the treatment of both angioid
streak62 and choroidal rupture.63,64 Our case with angioid streaklarization (CNV) patients after antivascular endothelial growth factor (anti-VEGF)
CNV PCV Angioid streaks Choroidal rupture
1 8 2 1
72.2 ± 33.9 286.3 ± 67.7 282.5 ± 44.5 216.0
08.2 ± 43.5 220.9 ± 62.7 258.5 ± 27.5 203.0
0.05 0.05
y; PIC ¼ punctate inner choroidopathy; PM ¼ pathological myopia.
Y.-H. Li et al. / Taiwan Journal of Ophthalmology 5 (2015) 76e84 83was a 50-year-old womanwith bilateral CNV and pseudoxanthoma
elasticum occurring on the neck. Interestingly, over the past 29
months of follow up (August 2012 to November 2014), she has
asked for a regular intravitreal injection of bevacizumab every 2
months to prevent any chance of recurrence. BCVA was increased
from 6/75 to 6/30 in the Snellen chart, with a gain of 25 letters in
the ETDRS chart for the right eye; the left eye BCVA in the Snellen
chart was maintained at 6/200 with persistent macular scar.
Our study exhibited a few notable disadvantages. The study was
retrospective and the case size was minimal, especially that of
angioid streaks and choroidal rupture. The follow-up duration was
also short and had wide variation due to the variable compliance of
the patients. A larger-scale study with each type of CNV in young
adults and a longer follow-up time is needed for further evaluation
of the efﬁcacy, treatment frequency, and predictability of intra-
vitreal injection of anti-VEGF.5. Conclusion
Our study reviewed 67 eyes with CNV in younger patients in
Taiwan. We described the most common etiology as PM, followed
by PIC, ICNV, and PCV. We observed an effective response to anti-
VEGF treatment in these subgroups. Elucidating the common eti-
ologies of CNV and the difference in prevalence compared with
Western countries may help the early diagnosis of CNV-related
problems and avoid further morbidity in younger patients.References
1. Bressler NM. Age-related macular degeneration is the leading cause of blind-
ness. JAMA. 2004;291:1900e1901.
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular
degeneration in the United States. Arch Ophthalmol. 2004;122:564e572.
3. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in
the year 2002. Bull World Health Organ. 2004;82:844e851.
4. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective.
Mol Vis. 2003;9:747e755.
5. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal
neovascularization. Optom Vis Sci. 2006;83:316e325.
6. Spaide RF. Choroidal neovascularization in younger patients. Curr Opin Oph-
thalmol. 1999;10:177e181.
7. Bird AC, Bressler NM, Bressler SB, et al. An international classiﬁcation and
grading system for age-related maculopathy and age-related macular degen-
eration. The International ARM Epidemiological Study Group. Surv Ophthalmol.
1995;39:367e374.
8. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal
neovascularization in young patients. Ophthalmology. 1996;103:1241e1244.
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporﬁn for
neovascular age-related macular degeneration. N Engl J Med. 2006;355:
1432e1444.
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-
controlled trial of ranibizumab for neovascular age-related macular degener-
ation: PIER Study year 1. Am J Ophthalmol. 2008;145:239e248.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-
related macular degeneration. N Engl J Med. 2006;355:1419e1431.
12. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neo-
vascular age-related macular degeneration: evidence from clinical trials. Br J
Ophthalmol. 2010;94:2e13.
13. Heier JS, Brown DM, Chong V, et al. Intravitreal aﬂibercept (VEGF trap-eye) in
wet age-related macular degeneration. Ophthalmology. 2012;119:2537e2548.
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-
guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for
neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:
566e583.
15. Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised
type 1 and type 2 submacular choroidal neovascular membranes. Am J Oph-
thalmol. 1998;126:59e69.
16. Chen PJ, Chen SN. Clinical characteristics of exudative age-related macular
degeneration in Taiwan. Taiwan J Ophthalmol. 2012;2:127e130.
17. Kwok AK, Lai TY, Chan CW, Neoh EL, Lam DS. Polypoidal choroidal vasculop-
athy in Chinese patients. Br J Ophthalmol. 2002;86:892e897.
18. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular
degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2007;245:
1441e1445.19. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of
exudative age-related macular degeneration in Japanese patients. Am J Oph-
thalmol. 2007;144:15e22.
20. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-
related macular degeneration. Retina. 2001;21:416e434.
21. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese
schoolchildren: 1983 to 2000. Ann Acad Med Singapore. 2004;33:27e33.
22. Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors
in adult Chinese in Singapore. Invest Ophthalmol Vis Sci. 2000;41:2486e2494.
23. Wu HM, Seet B, Yap EP, Saw SM, Lim TH, Chia KS. Does education explain
ethnic differences in myopia prevalence? A population-based study of young
adult males in Singapore. Optom Vis Sci. 2001;78:234e239.
24. Sun J, Zhou J, Zhao P, et al. High prevalence of myopia and high myopia in 5060
Chinese university students in Shanghai. Invest Ophthalmol Vis Sci. 2012;53:
7504e7509.
25. Jung SK, Lee JH, Kakizaki H, Jee D. Prevalence of myopia and its association with
body stature and educational level in 19-year-old male conscripts in seoul,
South Korea. Invest Ophthalmol Vis Sci. 2012;53:5579e5583.
26. He M, Zheng Y, Xiang F. Prevalence of myopia in urban and rural children in
mainland China. Optom Vis Sci. 2009;86:40e44.
27. Katz J, Tielsch JM, Sommer A. Prevalence and risk factors for refractive errors in
an adult inner city population. Invest Ophthalmol Vis Sci. 1997;38:334e340.
28. Vitale S, Sperduto RD, Ferris 3rd FL. Increased prevalence of myopia in the
United States between 1971e1972 and 1999e2004. Arch Ophthalmol.
2009;127:1632e1639.
29. French AN, Morgan IG, Burlutsky G, Mitchell P, Rose KA. Prevalence and 5- to 6-
year incidence and progression of myopia and hyperopia in Australian
schoolchildren. Ophthalmology. 2013;120:1482e1491.
30. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik Jr JM, Slakter JS. Bevacizumab
treatment for subfoveal choroidal neovascularization from causes other than
age-related macular degeneration. Arch Ophthalmol. 2008;126:941e945.
31. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion
after laser therapy for choroidal neovascularization in degenerative myopia.
Retina. 1990;10:239e243.
32. Pece A, Brancato R, Avanza P, Camesasca F, Galli L. Laser photocoagulation of
choroidal neovascularization in pathologic myopia: long-term results. Int
Ophthalmol. 1994;18:339e344.
33. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser
photocoagulation of juxtafoveal choroidal neovascularization in highly myopic
eyes. Eur J Ophthalmol. 2002;12:117e122.
34. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporﬁn therapy of sub-
foveal choroidal neovascularization in pathologic myopia: 2-year results of a
randomized clinical trialdVIP report no. 3. Ophthalmology. 2003;110:667e673.
35. Verteporﬁn in Photodynamic Therapy Study Group. Photodynamic therapy of
subfoveal choroidal neovascularization in pathologic myopia with verteporﬁn.
1-year results of a randomized clinical trialdVIP report no. 1. Ophthalmology.
2001;108:841e852.
36. Coco RM, de Souza CF, Sanabria MR. Photodynamic therapy for subfoveal and
juxtafoveal choroidal neovascularization associated with punctate inner cho-
roidopathy. Ocul Immunol Inﬂamm. 2007;15:27e29.
37. Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic
therapy and intravitreal triamcinolone for choroidal neovascularization sec-
ondary to punctate inner choroidopathy or of idiopathic origin: one-year re-
sults of a prospective series. Retina. 2008;28:71e80.
38. Chen YS, Lin JY, Tseng SY, Tang HF, Lee HJ, Lin YR. Photodynamic therapy of
idiopathic subfoveal choroidal neovascularization in Taiwanese patients: a 2-
year follow-up. Eye. 2009;23:314e319.
39. Kang HM, Kim YM, Koh HJ. Five-year follow-up results of photodynamic
therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155:
438e447.
40. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic
therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:
39e44.
41. Chen YS, Lin JY, Tseng SY, Yow SG, Hsu WJ, Tsai SC. Photodynamic therapy for
Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina.
2007;27:839e845.
42. Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK. Photodynamic therapy
with verteporﬁn for subfoveal choroidal neovascularisation of pathologic
myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J
Ophthalmol. 2004;88:1315e1319.
43. Pece A, Isola V, Vadala M, Matranga D. Photodynamic therapy with verteporﬁn
for subfoveal choroidal neovascularization secondary to pathologic myopia:
long-term study. Retina. 2006;26:746e751.
44. Schnurrbusch UE, Jochmann C, Wiedemann P, Wolf S. Quantitative assessment
of the long-term effect of photodynamic therapy in patients with pathologic
myopia. Graefes Arch Clin Exp Ophthalmol. 2005;243:829e833.
45. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized
controlled study of ranibizumab in patients with choroidal neovascularization
secondary to pathologic myopia. Ophthalmology. 2014;121:682e692.
46. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab as primary treatment of
choroidal neovascularization secondary to punctate inner choroidopathy: re-
sults of a 1-year prospective trial. Retina. 2012;32:1106e1113.
47. Kang HM, Koh HJ. Intravitreal anti-vascular endothelial growth factor therapy
versus photodynamic therapy for idiopathic choroidal neovascularization. Am J
Ophthalmol. 2013;155:713e719.
Y.-H. Li et al. / Taiwan Journal of Ophthalmology 5 (2015) 76e848448. Ijiri S, Sugiyama K. Short-term efﬁcacy of intravitreal aﬂibercept for patients
with treatment-naive polypoidal choroidal vasculopathy. Graefes Arch Clin Exp
Ophthalmol. 2015;253:351e357.
49. Inoue M, Arakawa A, Yamane S, Kadonosono K. Short-term efﬁcacy of intra-
vitreal aﬂibercept in treatment-naive patients with polypoidal choroidal vas-
culopathy. Retina. 2014;34:2178e2184.
50. Essex RW, Wong J, Jampol LM, Dowler J, Bird AC. Idiopathic multifocal
choroiditis: a comment on present and past nomenclature. Retina. 2013;33:
1e4.
51. Fung AT, Pal S, Yannuzzi NA, et al. Multifocal choroiditis without panuveitis:
clinical characteristics and progression. Retina. 2014;34:98e107.
52. Leung TG, Moradi A, Liu D, et al. Clinical features and incidence rate of
ocular complications in punctate inner choroidopathy. Retina. 2014;34:
1666e1674.
53. Zhang X, Wen F, Zuo C, et al. Clinical features of punctate inner choroidopathy
in Chinese patients. Retina. 2011;31:1680e1691.
54. Shimada H, Yuzawa M, Hirose T, Nakashizuka H, Hattori T, Kazato Y. Patho-
logical ﬁndings of multifocal choroiditis with panuveitis and punctate inner
choroidopathy. Jpn J Ophthalmol. 2008;52:282e288.
55. Arevalo JF, Adan A, Berrocal MH, et al. Intravitreal bevacizumab for inﬂam-
matory choroidal neovascularization: results from the Pan-American Collabo-
rative Retina Study Group at 24 months. Retina. 2011;31:353e363.
56. Ho AC, Yannuzzi LA, Pisicano K, DeRosa J. The natural history of idiopathic
subfoveal choroidal neovascularization. Ophthalmology. 1995;102:782e789.57. Wang F, Wang W, Yu S, et al. Functional recovery after intravitreal bev-
acizumab treatments for idiopathic choroidal neovascularization in young
adults. Retina. 2012;32:679e686.
58. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab for treatment of sub-
foveal idiopathic choroidal neovascularization: results of a 1-year prospective
trial. Am J Ophthalmol. 2012;153:300e306.
59. Kobayashi K, Mandai M, Suzuma I, Kobayashi H, Okinami S. Expression of es-
trogen receptor in the choroidal neovascular membranes in highly myopic
eyes. Retina. 2002;22:418e422.
60. Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after
intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J
Ophthalmol. 2013;156:652e660.
61. Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ. One-year outcomes of intra-
vitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Retina. 2011;31:846e856.
62. Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P.
Treatment of choroidal neovascularization due to angioid streaks: a compre-
hensive review. Retina. 2013;33:1300e1314.
63. Sheu SJ. Intravitreal ranibizumab for the treatment of choroidal neo-
vascularization secondary to endogenous endophthalmitis. Kaohsiung J Med Sci.
2009;25:617e621.
64. De Benedetto U, Battaglia Parodi M, Knutsson KA, et al. Intravitreal bev-
acizumab for extrafoveal choroidal neovascularization after ocular trauma.
J Ocul Pharmacol Ther. 2012;28:550e552.
